Business
Ability Biotherapeutics Appoints Angèle Maki, PhD, as Chief Business Officer
MONTREAL, December 09, 2025--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).
About this update from Bristol-myers Squibb Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lZe0A7te8pHHNJCx2oKAtg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/3ae5467b75c2baa421cf3f0ab3c28d5b","width":480,"height":252}},"lazy":false},{"type":"text","content":"MONTREAL, December 09, 2025--(BUSINESS WIRE)--Ability Biotherapeutics, a biotechnology company advancing logic-gated antibody therapies for cancer and autoimmune diseases, today announced the appointment of Angèle Maki, PhD, as Chief Business Officer (CBO).","length":257,"tagName":"p"},{"type":"text","content":"Dr. Maki brings over 20 years of biopharmaceutical industry experience, including leadership roles in business development, licensing, and corporate venture across both emerging biotech ventures and global pharmaceutical companies. Her background includes senior positions at industry-leading organizations such as Medarex (now part of Bristol Myers Squibb), Genentech, Merck & Co., Eli Lilly and Company, and Callio Therapeutics.","length":434,"tagName":"p"},{"type":"text","content":"In her new role, Dr. Maki will lead Ability’s business development strategy, driving global partnering efforts and cultivating new investor relationships to support the company’s growth. These strategic collaborations and financing initiatives will help advance autoimmune and oncology programs created with Ability’s proprietary AbiLeap™ platform toward the clinic, while unlocking its potential to generate new, highly specific, logic-gated antibody therapies across multiple indications.","length":490,"tagName":"p"},{"type":"text","content":""We are delighted to welcome Angèle to the leadership," said Giles Day, Co-Founder and Chief Executive Officer of Ability. "Her deep expertise in deal-making, licensing and strategic partnerships, together with her broad biotech and pharma experience and extensive global network, will be a major asset as we build strategic collaborations for the company. Her decision to step into an executive role after serving on our board of directors is a strong validation of Ability’s vision and momentum.&qu...